Company profile
PROCESSA PHARMACEUTICALS, INC.
NASDAQ:PCSABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| HALOFUGINONE | phase2 | — | 2 | terminated |
| PCS-499 | phase2 | — | 3 | completed, terminated |
| RODUCITABINE | phase1_2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04800562 | phase2 | terminated | 2021-04-12 | 2023-02-28 | Processa Pharmaceuticals | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica |
| NCT06568692 | phase2 | terminated | 2024-10-02 | 2026-07-29 | Processa Pharmaceuticals | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer |
| NCT04861987 | phase1 | completed | 2021-06-18 | 2024-06-12 | Processa Pharmaceuticals | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors |
| NCT03698864 | phase2 | completed | 2018-11-07 | 2020-02-25 | Processa Pharmaceuticals | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica |
| NCT02030067 | phase1_2 | completed | 2013-12-01 | 2019-07-01 | Processa Pharmaceuticals | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies |
FDA applications (0)
No records yet.